The prospect of biomanufacturing in space is accelerating the evolution of healthcare delivery and research in significant ways. From the unique research opportunities aboard the International Space Station (ISS) to the cutting-edge advancements in regenerative medicine, the potential of these
As the biopharmaceutical sector traverses the complex terrain of 2025, it encounters a multitude of challenges shaped by financial constraints, regulatory shifts, and evolving geopolitical dynamics. The industry is marked by notable changes detailed in Ernst & Young LLP's (EY) annual Biotech Beyond
Veranova has announced a major expansion of its Devens, Massachusetts facility, marking a significant step forward in the development and manufacturing of Antibody-Drug Conjugates (ADCs) and highly potent compounds. The company is investing $50 million to extend the facility by 9,000 square feet,
The biopharmaceutical industry finds itself at a crossroads as the ever-increasing global demand for pharmaceuticals necessitates a reevaluation of traditional manufacturing approaches. With escalating costs and inefficiencies hindering timely drug production, the sector is turning towards a
With the development of gene therapies in the treatment of genetic disorders, the recent advances made by CRISPR Therapeutics draw significant attention. The emergence of their flagship therapy, CASGEVY, presents a promising alternative, particularly for sickle cell disease. Sickle cell disease, a
In an era defined by environmental challenges and a greater emphasis on corporate responsibility, the biotech industry is at a crossroads where sustainability is not just a choice but an imperative. With an increasing number of companies committing to environmental, social, and governance (ESG)
